Legal Notice:
PAXIL® AND PAXIL CR™ USED IN CANADA DURING PREGNANCY

NOTICE OF SETTLEMENT APPROVAL

A class proceeding, Singh v GlaxoSmithKline Inc, Court File No. 1201-12838, commenced in the Alberta Court of King’s Bench, was certified regarding the selective serotonin reuptake inhibitor “paroxetine” that GlaxoSmithKline Inc. and certain affiliates (“GSK”) marketed in Canada under the brand names Paxil® and Paxil CR™. The class proceeding alleged that GSK did not warn physicians and patients in the Canadian Paxil® and Paxil CR™ product monographs that either drug posed a teratogenic risk when used during pregnancy. The allegations in the class proceeding are denied by GSK and have not been proven in court. The parties have agreed to settle the class proceeding rather than proceed to trial.

WHO IS ELIGIBLE FOR THE SETTLEMENT?

To be eligible to participate in this settlement, you must be a member of the class, or the estate or legal representative of a class member. The class is defined as:

women who were prescribed Paxil® or Paxil CR™ in Canada and subsequently aborted, delivered, or miscarried children with congenital malformations after ingesting either drug while pregnant, family members who may make claims under Family Compensation Legislation following the death of, or injury to such children, children born alive to such women, and provincial and territorial governments who paid health care costs on their behalf.

SETTLEMENT TERMS

You can obtain a copy of the settlement agreement by contacting Class Counsel or the Claims Administrator at the addresses below. In summary, GSK agreed to pay an all-inclusive sum of $7,500,000 CAD to settle the allegations in the lawsuit. This money is available to compensate class members, to pay provincial and territorial governments for health care costs they paid on behalf of class members, and to pay legal fees and expenses related to the prosecution of this class proceeding and the administration of the settlement.

HOW TO MAKE A CLAIM

Class members must submit a Claim Form and upload supporting documentation to the Claims Administrator in the online claims administration portal at https://portal.paxilbirthdefectsclassaction.ca/ or mail or fax to the address for the Claims Administrator, Trilogy Class Action Services, listed below before January 14, 2025. The Claims Officer will then determine each class member’s entitlement to compensation based on that supporting documentation.

ADDITIONAL INFORMATION

This is not an advertisement or solicitation by a lawyer. The court has approved the content of this notice, and it affects your legal rights. You should seek independent legal advice to consider your options. You can review additional documents related to the class proceeding at www.paxilbirthdefectsclassaction.ca. You may also call 1-877-400-1211 or e-mail with inquiries about the class proceeding and for further information on whether you are a class member and how you may participate further.

For more information about the lawsuit and/or to obtain a Claim Form, please contact Class Counsel at:
1000 - 7 Avenue SW Suite 400
Calgary, Alberta
T2P 5L5
Clint Docken KC | Casey R. Churko
Tel: (306) 540-2284
Fax: (639) 739-2223
cchurko@napolilaw.com

or contact the Claims Administrator at:
Paxil Birth Defects Class Action
c/o Trilogy Class Action Services
117 Queen Street, P.O. Box 1000
Niagara-on-the-Lake, Ontario
L0S 1J0
Tel: (877) 400-1211
Fax: (416) 342-1761
E-mail: